| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.46 | 0.04 (+0.42%) | 3.78 - 10.48 | 1.3 million (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 9.45 |
|---|---|
| Previous Close | 9.42 |
| Day's Range | 8.79 - 9.66 |
| Market Cap | 397.0M |
| Avg Volume (10 Day) | 431.1K |
| Price/Earnings (Trailing 12 Mo.) | 105.1x |
| Earnings Per Share (Trailing 12 Mo.) | 0.09 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Sucampo to be Added to the NASDAQ Biotechnology Index
Business Wire - Wednesday 05/15/2013 6:45 AM ET
Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th
Business Wire - Monday 05/13/2013 6:45 AM ET
Sucampo Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operating Results
Business Wire - Tuesday 05/07/2013 4:05 PM ET
Sucampo Pharmaceuticals Announces First Quarter 2013 Results and Operating Highlights Teleconference and Webcast
Business Wire - Tuesday 04/30/2013 6:45 AM ET
FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain
Business Wire - Tuesday 04/23/2013 6:45 AM ET
| SCMP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 47.21% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 1.56 | |
| LT Debt/Equity | 0.84 | |
| Earnings Yield | 0.95% | |
| Price/Sales | 4.73 |
| Company | Last | Change |
|---|---|---|
| Lannett Company Inc | 12.29 | +1.32% |
| Dynavax Technologies Corp | 2.51 | +0.80% |
| Simcere Pharmaceutical Group | 9.26 | -0.11% |
| Synergy Pharmaceuticals Inc | 5.30 | +4.13% |
| Depomed Inc | 5.48 | +1.48% |
Data is delayed by at least 15 min.